An early-stage life sciences company, Brevitest Technologies is organized around development of a biomedical assay platform technology that would enable and support perform ELISAs at the point of care. Potentially, such a platfrom w/could allow consumers, patients, caregivers, and others more easily to detect and quantify molecules of interest from a variety of sample types: blood, saliva, urine and water. Providing for a compact point-of-care diagnostics that is sensitive, specific and rapid, the BreviTest platform could be applied to a broad array of diagnostic tests - in emergency and non-emergency settings, allergen detection, home monitoring of chronic diseases as well as physiological conditions.
